Novo Nordisk spotlights future innovations within diabetes as insulin sales recede

Novo Nordisk has two types of insulin in the works which would finally bring some much-needed innovation to the area, says Novo exec Camilla Sylvest, pointing out that the area has not received enough attention for a while.

Camilla Sylvest, executive vice president for commercial strategy and corporate affairs at Novo Nordisk | Photo: Novo Nordisk / PR

A number of bleak years for pharmaceutical firm Novo Nordisk’s insulin business, particularly in the US, have been replaced by a bright outlook.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs